Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There were no statistically significant differences between the two groups regarding serum levels of total calcium, vitamin D, phosphorus, HbA1C, creatinine, urea, and CRP as shown in Table 2.Laboratory data of the patients (n = 100)Total (n = 100)COVID (n = 56)Non-COVID (n = 44)Test of sigpFerritin (µg/L) Median (min.: max.)(n = 56)(n = 56): 486 (154 to 1213)487 (154 to 1213)CRP (mg/dl) Mean ± SD6.44 ± 3.796.45 ± 2.915.98 ± 3.02t = 0.7880.43HbA1C % Mean ± SD6.99 ± 1.807.01 ± 1.816.97 ± 1.82t = 0.0900.929Creatinine (µmol/L) Mean ± SD72.96 ± 49.6781.0 ± 48.9868.90 ± 40.23t = 1.3250.188Urea (mmol/L) Median (min.: max.)4.2 (2.1 to 42)4.0 (2.4 to 38.1)4.35 (2.1 to 42)U = 1130.50.481Vitamin D level (nmol/L) Median (min.: max.)47.3(10.42 to 162.3)44.7 (20 to 162.3)55.0 (10.4 to 123.1)U = 999.00.106Calcium (mmol/L) Mean ± SD2.32 ± 0.132.29 ± 0.132.34 ± 0.11t = 1.9090.059Phosphorus (mmol/L) Mean ± SD1.10 ± 0.241.08 ± 0.271.13 ± 0.20t = 1.1070.271SD standard deviation, t Student t-test, U Mann: Whitney test, χ2 chi-square test, CRP C-reactive protein, HbA1C glycosylated hemoglobin, COVID coronavirus disease, p p value for comparing between COVID and non-COVID*Statistically significant at p ≤ 0.05
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were selected from the osteoporosis clinic department of Rheumatology and Rehabilitation Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone mineral density changes in osteoporotic and osteopenic patients after COVID-19 infection
Study design awaiting verification · Egyptian Rheumatology and Rehabilitation · 2022
Original publication title
Bone mineral density changes in osteoporotic and osteopenic patients after COVID-19 infection
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Coronavirus disease 2019 (COVID-19) infection is linked to high levels of inflammatory cytokines and prolonged immobilization; furthermore, corticosteroid treatment leads to increased bone loss and resorption. We aimed to study the change in bone mineral density (BMD) after COVID-19 infection in osteoporotic and osteopenic patients. One hundred osteoporotic or osteopenic patients were selected in this single-center retrospective study; the patients were divided into two groups. Group 1 included 56 patients who got COVID-19 infection. Group 2 included 44 patients who did not get COVID-19 infection.
BMD was assessed at baseline, after 9 months of COVID infection, and then after 1 year follow-up using dual energy x-ray absorptiometry (DXA) scan.
Source: BackgroundAbstract: Results
There was no significant difference between two groups regarding demographic data (p > 0.05); there was a significant decrease in BMD of the lumbar region and femur at 9 months as compared to baseline in group1 (p < 0.001), while there was a significant increase in the lumbar BMD of osteoporotic patients who did not get COVID infection after 21 months. Concerning activity of COVID infection, there was a significant difference between the three subgroups of COVID patients regarding percentage of change in BMD after 9 months, the severe group having the highest decrease in BMD (p < 0.001).
Source: ResultsAbstract: Conclusions
COVID-19 may have deleterious effect on BMD in osteoporotic patients. It is recommended to assess BMD in osteoporotic/osteopenic patients who got COVID infection to detect if there is an increased risk of fracture which may necessitate post-COVID change in the therapeutic intervention plan.
Source: ConclusionsAuthors’ abstract
Background
Coronavirus disease 2019 (COVID-19) infection is linked to high levels of inflammatory cytokines and prolonged immobilization; furthermore, corticosteroid treatment leads to increased bone loss and resorption. We aimed to study the change in bone mineral density (BMD) after COVID-19 infection in osteoporotic and osteopenic patients. One hundred osteoporotic or osteopenic patients were selected in this single-center retrospective study; the patients were divided into two groups. Group 1 included 56 patients who got COVID-19 infection. Group 2 included 44 patients who did not get COVID-19 infection.
BMD was assessed at baseline, after 9 months of COVID infection, and then after 1 year follow-up using dual energy x-ray absorptiometry (DXA) scan.
Results
There was no significant difference between two groups regarding demographic data (p > 0.05); there was a significant decrease in BMD of the lumbar region and femur at 9 months as compared to baseline in group1 (p < 0.001), while there was a significant increase in the lumbar BMD of osteoporotic patients who did not get COVID infection after 21 months. Concerning activity of COVID infection, there was a significant difference between the three subgroups of COVID patients regarding percentage of change in BMD after 9 months, the severe group having the highest decrease in BMD (p < 0.001).
Conclusions
COVID-19 may have deleterious effect on BMD in osteoporotic patients. It is recommended to assess BMD in osteoporotic/osteopenic patients who got COVID infection to detect if there is an increased risk of fracture which may necessitate post-COVID change in the therapeutic intervention plan.
Supplementary Information
The online version contains supplementary material available at 10.1186/s43166-022-00165-7.
Publication and source details
Original title: Bone mineral density changes in osteoporotic and osteopenic patients after COVID-19 infection
Samah Hamdy Elmedany; Omaima Ibrahim Badr; Mohammed Hassan Abu-Zaid; Samar Abd Alhamed Tabra
Egyptian Rheumatology and Rehabilitation · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T10:33:35.353270+00:00
DOI: 10.1186/s43166-022-00165-7 · PMC9746586